Salt Lake City, Utah-based CoNextions® Inc. has named its own Daniel Gruppo as president and chief executive officer.
Introducing CoNextions New President and CEO
Gruppo succeeds Jeff Barnes who served as CoNextions chief executive officer since 2017. Barnes will stay with CoNextions as executive chairman of the board of directors.
Gruppo has over 14 years of leadership experience. He joined CoNextions in 2016 as its executive vice president of global sales and marketing.
Prior to joining CoNextions, Gruppo spent almost eight years with Stryker Trauma and Extremities in several executive sales and marketing positions. His last role at Stryker was vice president upper extremities sales and marketing. Prior to that position, Gruppo spent almost four years as the global vice president of marketing.
In his public statement regarding the management change, Barnes said, “Dan’s management experience at Stryker, coupled with his sales and marketing acumen, make him well suited to assume this role.”
Barnes continued, “Erik Kubiak, M.D., founder and board member of CoNextions, and I are confident that Dan can make CoNextions the company we envision.”
Founded in 2011, CoNextions is a privately held medical device company focused on “achieving safer, stronger, and more durable tendon repairs worldwide marked by faster rehabilitation, fewer complications, and lower long-term costs.”
Its latest device is the CoNextions TR Tendon Repair System. The company is currently launching the system across the United States and in a number of select countries. According to the company, the CoNextions TR Tendon Repair System “can be used for tendon approximation for various clinical indications in the hand, wrist, forearm, foot, and ankle.”
OTW spoke with Gruppo about his new position: “It is exciting for me to be part of a company launching a device that will completely overhaul the way a common procedure is done.”
Gruppo continued, “I wholeheartedly believe that over the next few years the CoNextions TR Tendon Repair System will replace suture as the standard of care.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.